Tiziana life sciences announces positive six-month clinical results in multiple sclerosis patients treated with intranasal foralumab

New york, oct. 16, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced six-month data showing positive clinical improvements related to modified fatigue impact scale (mfis) scores and similar important clinical measures of physical function in foralumab-treated, non-active secondary progressive multiple sclerosis (na-spms) patients participating in an expanded access (ea) program.   this follows on from previously announced positive six-month pet scan data which was presented at ectrims 2023.
TLSA Ratings Summary
TLSA Quant Ranking